Literature DB >> 17990914

A murine model of infantile neuronal ceroid lipofuscinosis-ultrastructural evaluation of storage in the central nervous system and viscera.

Nancy Galvin1, Carole Vogler, Beth Levy, Attila Kovacs, Megan Griffey, Mark S Sands.   

Abstract

Infantile neuronal ceroid lipofuscinosis (INCL), also known as Santavuori-Haltia disease, is an inherited neurodegenerative disorder caused by a mutation in the gene encoding the lysosomal enzyme palmitoyl-protein-thioesterase-1 (PPT1). Fatty acid-modified proteins are not degraded and accumulate as granular osmiophilic deposits in cells in the central nervous system; patients have blindness, seizures, progressive psychomotor deterioration, and die in early childhood. Although the disease manifests clinically primarily with neurological symptoms, visceral storage also accumulates. A murine model of INCL due to PPT1 deficiency exhibits clinical findings and pathology similar to those seen in patients with INCL. Homozygous PPT1-deficient mice have a shortened life span and neurological abnormalities including seizures, blindness, and mental and motor deficits. Widespread granular osmiophilic deposits (GRODs) accumulate in lysosomes in neurons and glia in the brain, retinal cells, kidney glomerular cells, aortic smooth muscle cells, and, in lesser amounts, in the fixed-tissue macrophage system. Accumulation of GRODs in aortic smooth muscle cells is accompanied by abnormalities in cardiac function and aortic root dilatation. This PPT1-deficient murine model is a well-defined genetic system that can be used to test potential therapies for lysosomal storage disease and to study the pathophysiology of INCL.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17990914      PMCID: PMC2789460          DOI: 10.2350/07-03-0242.1

Source DB:  PubMed          Journal:  Pediatr Dev Pathol        ISSN: 1093-5266


  26 in total

Review 1.  Genetics of the neuronal ceroid lipofuscinoses.

Authors:  L Peltonen; M Savukoski; J Vesa
Journal:  Curr Opin Genet Dev       Date:  2000-06       Impact factor: 5.578

2.  Disruption of PPT1 or PPT2 causes neuronal ceroid lipofuscinosis in knockout mice.

Authors:  P Gupta; A A Soyombo; A Atashband; K E Wisniewski; J M Shelton; J A Richardson; R E Hammer; S L Hofmann
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-20       Impact factor: 11.205

3.  Successive neuron loss in the thalamus and cortex in a mouse model of infantile neuronal ceroid lipofuscinosis.

Authors:  Catherine Kielar; Lucy Maddox; Ellen Bible; Charlie C Pontikis; Shannon L Macauley; Megan A Griffey; Michael Wong; Mark S Sands; Jonathan D Cooper
Journal:  Neurobiol Dis       Date:  2006-10-12       Impact factor: 5.996

Review 4.  Neurodegenerative disease: the neuronal ceroid lipofuscinoses (Batten disease).

Authors:  H M Mitchison; S E Mole
Journal:  Curr Opin Neurol       Date:  2001-12       Impact factor: 5.710

5.  Hematopoietic stem cell transplantation in infantile neuronal ceroid lipofuscinosis.

Authors:  T Lönnqvist; S L Vanhanen; K Vettenranta; T Autti; J Rapola; P Santavuori; U M Saarinen-Pihkala
Journal:  Neurology       Date:  2001-10-23       Impact factor: 9.910

6.  Cardiac pathology in neuronal ceroid lipofuscinoses--a clinicopathologic correlation in three patients.

Authors:  I L Hofman; A C van der Wal; K P Dingemans; A E Becker
Journal:  Eur J Paediatr Neurol       Date:  2001       Impact factor: 3.140

7.  Hippocampal lesions in the neuronal ceroid lipofuscinoses.

Authors:  M Haltia; R Herva; J Suopanki; M Baumann; J Tyynelä
Journal:  Eur J Paediatr Neurol       Date:  2001       Impact factor: 3.140

8.  Lysosomal ceroid depletion by drugs: therapeutic implications for a hereditary neurodegenerative disease of childhood.

Authors:  Z Zhang; J D Butler; S W Levin; K E Wisniewski; S S Brooks; A B Mukherjee
Journal:  Nat Med       Date:  2001-04       Impact factor: 53.440

9.  The effects of lysosomotropic agents on normal and INCL cells provide further evidence for the lysosomal nature of palmitoyl-protein thioesterase function.

Authors:  Jui-Yun Lu; Linda A Verkruyse; Sandra L Hofmann
Journal:  Biochim Biophys Acta       Date:  2002-06-13

10.  Disruption of PPT2 in mice causes an unusual lysosomal storage disorder with neurovisceral features.

Authors:  Praveena Gupta; Abigail A Soyombo; John M Shelton; Ian G Wilkofsky; Krystyna E Wisniewski; James A Richardson; Sandra L Hofmann
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-03       Impact factor: 11.205

View more
  16 in total

1.  Combination small molecule PPT1 mimetic and CNS-directed gene therapy as a treatment for infantile neuronal ceroid lipofuscinosis.

Authors:  Marie S Roberts; Shannon L Macauley; Andrew M Wong; Denis Yilmas; Sarah Hohm; Jonathan D Cooper; Mark S Sands
Journal:  J Inherit Metab Dis       Date:  2012-02-07       Impact factor: 4.982

2.  Considerations for the treatment of infantile neuronal ceroid lipofuscinosis (infantile Batten disease).

Authors:  Mark S Sands
Journal:  J Child Neurol       Date:  2013-09       Impact factor: 1.987

3.  Synergistic effects of central nervous system-directed gene therapy and bone marrow transplantation in the murine model of infantile neuronal ceroid lipofuscinosis.

Authors:  Shannon L Macauley; Marie S Roberts; Andrew M Wong; Francesca McSloy; Adarsh S Reddy; Jonathan D Cooper; Mark S Sands
Journal:  Ann Neurol       Date:  2012-02-24       Impact factor: 10.422

4.  Intravenous high-dose enzyme replacement therapy with recombinant palmitoyl-protein thioesterase reduces visceral lysosomal storage and modestly prolongs survival in a preclinical mouse model of infantile neuronal ceroid lipofuscinosis.

Authors:  Jie Hu; Jui-Yun Lu; Andrew M S Wong; Linda S Hynan; Shari G Birnbaum; Denis S Yilmaz; Barbara M Streit; Ewelina M Lenartowicz; Thomas C M Thompson; Jonathan D Cooper; Sandra L Hofmann
Journal:  Mol Genet Metab       Date:  2012-05-22       Impact factor: 4.797

Review 5.  Pathogenesis and therapies for infantile neuronal ceroid lipofuscinosis (infantile CLN1 disease).

Authors:  Jacqueline A Hawkins-Salsbury; Jonathan D Cooper; Mark S Sands
Journal:  Biochim Biophys Acta       Date:  2013-06-06

6.  Histochemical localization of palmitoyl protein thioesterase-1 activity.

Authors:  Joshua T Dearborn; Subramania Ramachandran; Charles Shyng; Jui-Yun Lu; Jonah Thornton; Sandra L Hofmann; Mark S Sands
Journal:  Mol Genet Metab       Date:  2015-11-11       Impact factor: 4.797

7.  Metabolic adaptations to interrupted glycosaminoglycan recycling.

Authors:  Josh C Woloszynek; Atilla Kovacs; Kevin K Ohlemiller; Marie Roberts; Mark S Sands
Journal:  J Biol Chem       Date:  2009-08-21       Impact factor: 5.157

8.  Synergistic effects of treating the spinal cord and brain in CLN1 disease.

Authors:  Charles Shyng; Hemanth R Nelvagal; Joshua T Dearborn; Jaana Tyynelä; Robert E Schmidt; Mark S Sands; Jonathan D Cooper
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-03       Impact factor: 11.205

Review 9.  Neuronal Ceroid Lipofuscinosis: Potential for Targeted Therapy.

Authors:  Nicola Specchio; Alessandro Ferretti; Marina Trivisano; Nicola Pietrafusa; Chiara Pepi; Costanza Calabrese; Susanna Livadiotti; Alessandra Simonetti; Paolo Rossi; Paolo Curatolo; Federico Vigevano
Journal:  Drugs       Date:  2021-01       Impact factor: 9.546

10.  Cerebellar pathology and motor deficits in the palmitoyl protein thioesterase 1-deficient mouse.

Authors:  Shannon L Macauley; David F Wozniak; Catherine Kielar; Yun Tan; Jonathan D Cooper; Mark S Sands
Journal:  Exp Neurol       Date:  2009-02-10       Impact factor: 5.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.